Karyopharm Therapeutics reported $71.35M in Cash and Equivalent for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Amgen AMGN:US USD 9.5B 4.3B
AstraZeneca AZN:LN USD 4.46B 359M
Astrazeneca AZN:US USD 4.46B 359M
Avrobio Inc AVRO:US USD 115.97M 16.44M
Biocryst Pharmaceuticals BCRX:US USD 461.19M 43.71M
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Eli Lilly And LLY:US USD 2.62B 5.5M
Enanta Pharmaceuticals ENTA:US USD 43.99M 15.63M
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Karyopharm Therapeutics KPTI:US USD 71.35M 10.9M
Macrogenics MGNX:US USD 83.99M 62.52M
Mirati Therapeutics MRTX:US USD 173.53M 71.97M
Nektar Therapeutics NKTR:US USD 105.76M 28.21M
Novartis NVS:US USD 8.73B 5.1B
Novartis NOVN:VX USD 8.73B 5.1B
Regeneron Pharmaceuticals REGN:US USD 3.49B 96.2M
Sangamo Biosciences SGMO:US USD 94.57M 23.14M
Takeda 4502:JP JPY 798.14B 152.15B
Tg Therapeutics TGTX:US USD 109.86M 37.21M
Ultragenyx Pharmaceutical RARE:US USD 391.65M 231.78M
Xencor XNCR:US USD 52.65M 3.24M
YTE INCY:US USD 2.69B 255.24M